ReviewNutrients2025
Melatonin and Vitamins: A Promising Combination to Augment Conventional Anticancer Therapies.
Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Isocyanate-Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3-Mediated Extracellular Matrix Remodeling and cGAS-STING Pathway Activation in Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A malignant symbiosis: The neuro-metabolic symphony rewires the tumor microenvironment.Neoplasia (New York, N.Y.) · 2026Review
- Review
- Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies.Oncology research · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge, requiring new adjunctive therapies. Integrative oncology, which combines conventional treatments with complementary agents, has gained attention for improving patient outcomes. Melatonin, a potent antioxidant and immunomodulator, has shown promise in cancer therapy. Recent evidence suggests that combining melatonin with vitamins-particularly vitamin D, vitamin C, and vitamin E-may enhance its anticancer effects through synergistic mechanisms. Melatonin exerts anticancer effects by regulating oxidative stress, apoptosis, and immune responses. Vitamin D enhances immune modulation, while vitamins C and E provide antioxidant and cytoprotective benefits. Their combined action may improve tumor suppression and reduce treatment-induced toxicity. However, despite promising preclinical data, clinical studies on melatonin-vitamins synergy remain limited. This review explores the molecular interactions, current evidence, and research gaps in melatonin-vitamin combinations for cancer therapy. Future studies should focus on mechanistic insights, optimal dosing, and clinical trials to establish their role in integrative oncology. Unlocking this potential could enhance existing cancer treatment strategies and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.